Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Intellia Therapeutics, Inc. (NTLA : NSDQ)

• Company Description    Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.? Number of Employees: 403

• Price / Volume Information    Yesterday's Closing Price: $12.27 Daily Weekly Monthly 20 Day Moving Average: 10,077,121 shares Shares Outstanding: 107.35 (millions) Market Capitalization: $1,316.61 (millions) Beta: 2.37 52 Week High: $28.25 52 Week Low: $5.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -39.99% -40.94% 12 Week 7.02% -0.54% Year To Date 5.19% -9.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 Erie Street Suite 130 - Cambridge,MA 02139 USA ph: 857-285-6200 fax: - brittany.chaves@intelliatx.com http://www.intelliatx.com

• General Corporate Information    Officers John M. Leonard - President; Chief Executive Officer and Director Edward J. Dulac - Executive Vice President; Chief Financial Officer Michael P. Dube - Vice President; Chief Accounting Officer Muna Bhanji - Director Bill Chase - Director Peer Information Intellia Therapeutics, Inc. (CORR.) Intellia Therapeutics, Inc. (RSPI) Intellia Therapeutics, Inc. (CGXP) Intellia Therapeutics, Inc. (BGEN) Intellia Therapeutics, Inc. (GTBP) Intellia Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45826J105 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 107.35 Most Recent Split Date: (:1) Beta: 2.37 Market Capitalization: $1,316.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.98 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 25.97% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.78 Price/Cash Flow: - Price / Sales: 24.91 EPS Growth vs. Year Ago Period: 24.43% vs. Previous Quarter: 10.00% Sales Growth vs. Year Ago Period: 104.76% vs. Previous Quarter: -14.33% ROE 09/30/25 - - 06/30/25 - -57.48 03/31/25 - -56.06 ROA 09/30/25 - - 06/30/25 - -45.04 03/31/25 - -44.25 Current Ratio 09/30/25 - - 06/30/25 - 5.19 03/31/25 - 4.90 Quick Ratio 09/30/25 - - 06/30/25 - 5.19 03/31/25 - 4.90 Operating Margin 09/30/25 - - 06/30/25 - -905.18 03/31/25 - -1,102.68 Net Margin 09/30/25 - - 06/30/25 - -908.48 03/31/25 - -1,154.10 Pre-Tax Margin 09/30/25 - - 06/30/25 - -908.48 03/31/25 - -1,154.10 Book Value 09/30/25 - - 06/30/25 - 6.91 03/31/25 - 7.53 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©